Partnering
Licensing Opportunities
HOME
>
Partnering
>
Licensing Opportunities
Advalife Science considers licensing, co-development and other forms of partnering for its new drug candidates, related technologies and intellectual property.
Contents
01
What is available for licensing
03
How an enquiry proceeds
02
Information we can disclose
Contents
01
What is available for licensing
02
Information we can disclose
03
How an enquiry proceeds
Opportunities
TECHNOLOGY & IP
Technology and intellectual property
Licensing or co-development of the technologies, granted patents and other intellectual property relating to our new drug candidates, considered case by case.
PROGRAM
Development programmes
Licensing, joint research and co-development of new drug candidates and development programmes, on a programme-by-programme basis.
TERRITORY & RIGHTS
Territory and scope of rights
Territory, indication, and development, manufacturing, commercialisation and other rights are discussed case by case.
CO-DEVELOPMENT
Co-development
Co-development covering manufacturing and CMC, non-clinical work and clinical development, discussed according to the partner’s capabilities and development strategy.
TECHNOLOGY & IP
技術・知的財産
新規医薬品候補に関連する技術、公開済み特許その他の知的財産について、案件ごとにライセンスまたは共同開発を検討します。
PROGRAM
開発プログラム
新規医薬品候補・開発プログラムについて、プログラム単位でのライセンス、共同研究、共同開発等を検討します。
TERRITORY & RIGHTS
地域・権利範囲
新規医薬品候補に関連する技術、公開済み特許その他の知的財産について、案件ごとにライセンスまたは共同開発を検討します。
CO-DEVELOPMENT
共同開発
製造・CMC、非臨床、臨床開発等を含む共同開発について、パートナーの機能・開発戦略に応じて協議します。
Selected public IP
Advalife Science is building intellectual property — granted patents, PCT international publications and others — across several research and development areas, including oncology. For the published information in detail, see Intellectual Property Strategy.
Scope of rights, third-party rights, freedom to operate and exclusivity are confirmed in the due diligence carried out for each case.
Materials
Before an NDA
Published intellectual property information, outlines of development programmes and other information that can be made public.
After an NDA
Unpublished research data, non-clinical information, manufacturing and CMC information, development plans and whatever else is needed to assess the case.
Due Diligence / Data Room
As a case proceeds, the information required for due diligence is disclosed in a controlled environment.
Process
STEP 01
Initial enquiry
Tell us what interests you — the technology, the development programme, the territory and the form of collaboration.
STEP 02
Initial discussion
Working from published information and outline materials, we establish each side’s interest, the programme concerned, the development approach and the scope for working together.
STEP 03
NDA / CDA
A confidentiality agreement is concluded before any unpublished information is disclosed.
STEP 04
Due diligence and negotiation
Research data, non-clinical work, CMC, intellectual property and development plans are examined as required, and the subject matter, territory, scope of rights, division of roles and principal terms are negotiated.
For the process in detail, see Business Development Process.
Nothing on this page is a commitment to grant a licence over any particular development asset or item of intellectual property, nor a legal offer. Whether a licence is granted, over which rights and on what terms, is determined through due diligence and individual negotiation and agreement.
PARTNERING
Discuss a partnership
We welcome enquiries about our assets, joint research, co-development and licensing.